Polyphor gains financial cushion ahead of Phase III readout of lone clinical program

A new equity financing should give Polyphor a little more financial breathing room as the Swiss biotech tries to broaden its pipeline and move away from an all-or-nothing Phase III coin flip in 1Q21.

Polyphor AG (SIX:POLN) announced a staggered convertible bond deal on July 28 in which French firm IRIS could purchase

Read the full 528 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers